Nuvectis Pharma (NVCT) awards 30,000 restricted shares to finance VP

Rhea-AI Filing Summary

Carson Michael J. reported acquisition or exercise transactions in this Form 4 filing.

Nuvectis Pharma, Inc. granted Vice President, Finance Michael J. Carson 30,000 shares of restricted common stock on August 3, 2026. These shares will fully vest on August 3, 2027, subject to his continued service. Following this award, he directly holds 230,118 shares of common stock, including restricted shares.

Insider Trade Summary

Net Buyer: 30,000 shares

Net Buy 1 txn

Insider Carson Michael J.

Role Vice President, Finance

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1, F2	30,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 230,118 shares (Direct)

Footnotes (2)

1. F1. The 30,000 shares of restricted common stock will fully vest on August 3, 2027, subject to Mr. Carson's continued service on such date.
2. F2. Includes shares of restricted common stock.

Key Figures

Restricted shares granted: 30,000 shares Per-share grant price: $0.0000 per share Shares owned after grant: 230,118 shares +1 more

4 metrics

Restricted shares granted 30,000 shares Grant of restricted common stock to VP Finance on August 3, 2026

Per-share grant price $0.0000 per share Reported price for the 30,000-share restricted stock award

Shares owned after grant 230,118 shares Total direct common stock holdings for Michael J. Carson post-transaction, including restricted shares

Vesting date August 3, 2027 Date on which the 30,000 restricted shares will fully vest, subject to continued service

Key Terms

restricted common stock, fully vest, continued service

3 terms

restricted common stock financial

"The 30,000 shares of restricted common stock will fully vest on August 3, 2027"

Restricted common stock is company shares that carry limits on selling or transferring for a set period or until certain conditions are met, like time-based vesting or regulatory clearance. Think of them as shares in a locked box that gradually open; they can become freely tradable later but initially reduce the number of shares available on the market. Investors watch restricted stock because its eventual release can change a company’s share supply, affect stock price, and influence control and dilution.

fully vest financial

"The 30,000 shares of restricted common stock will fully vest on August 3, 2027"

continued service financial

"subject to Mr. Carson's continued service on such date"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/05/2026 - 05:26 PM Accepted by SEC EDGAR 08/05/2026 - 05:26 PM Learn about SEC filing dates

FAQ

What insider stock transaction did Nuvectis Pharma (NVCT) report for Michael J. Carson?

Nuvectis Pharma reported that Vice President, Finance Michael J. Carson received 30,000 shares of restricted common stock on August 3, 2026. This compensation-related award increased his direct holdings to 230,118 shares of Nuvectis Pharma common stock, including the newly granted restricted shares.

When do the 30,000 restricted shares granted by NVCT to Michael J. Carson vest?

The 30,000 shares of restricted common stock granted to Michael J. Carson will fully vest on August 3, 2027. Vesting is expressly conditioned on his continued service with the company through that date, meaning he must remain employed for the shares to vest.

How many Nuvectis Pharma (NVCT) shares does Michael J. Carson own after this grant?

After the August 3, 2026 award, Michael J. Carson directly owns 230,118 shares of Nuvectis Pharma common stock. This figure includes shares of restricted common stock, as noted in the disclosure footnote, and represents his total reported direct beneficial ownership post-grant.

Was the NVCT insider stock grant to Michael J. Carson made under a Rule 10b5-1 trading plan?

The disclosure indicates the Rule 10b5-1 checkbox was not marked for this transaction. That means the reported 30,000-share restricted stock grant is not identified as being made pursuant to a pre-arranged Rule 10b5-1 trading plan in this report.

What type of security did Nuvectis Pharma (NVCT) grant to its Vice President, Finance?

Nuvectis Pharma granted Michael J. Carson 30,000 shares of restricted common stock. These shares carry vesting conditions and will fully vest on August 3, 2027, contingent on his continued service with the company through that vesting date.

Did Michael J. Carson pay a purchase price for the 30,000 NVCT shares granted?

The transaction shows a per-share price of $0.0000, indicating no cash purchase price for the award. This aligns with a compensation-related grant of restricted common stock rather than an open-market purchase of Nuvectis Pharma shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carson Michael J.

(Last) (First) (Middle)

C/O NUVECTIS PHARMA, INC.

1 BRIDGE PLAZA, SUITE 275

(Street)

FORT LEE NEW JERSEY 07024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nuvectis Pharma, Inc. [ NVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Vice President, Finance

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/03/2026		A		30,000(1)	A	$0	230,118(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The 30,000 shares of restricted common stock will fully vest on August 3, 2027, subject to Mr. Carson's continued service on such date.

2. Includes shares of restricted common stock.

	/s/ Michael Carson	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)